HER2-positive breast cancer
Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment
... HR−/HER2+ breast cancers showed increased TIL scores compared to HR-positive breast cancers, and a high TIL score was associated with a higher pCR rate ...and cancer outcomes both ...
15
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.
... adjuvant breast cancer trials: The STEEP ...in cancer trials: Bridging the ...anti- cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Bene fit Scale ...
12
Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study
... early-stage HER2-positive breast cancer [8] ...in HER2 positive breast cancer also conclude that the association of bev- acizumab and trastuzumab may be synergistic ...
10
Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer
... of HER2 concentrations (0 to 1694 amol/µg) in breast cancer samples, all considered as HER2-positive by ...as positive with gold standard IHC and/or FISH but had low amount of ...
17
What do we learn from HER2-positive breast cancer genomic profiles?
... the HER2 {AU Query: per journal style, abbreviations of gene names should be in italics; please confirm whether this rule is applied correctly throughout the text} gene are currently proposed {AU Query: ...
7
A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers
... HER2-positive breast cancer has long proven to be a clinically distinct class of breast cancers for which several targeted therapies are now ...the HER2-positive disease ...
10
Anti-HER2 vaccines: new prospects for breast cancer therapy.
... that cancer vaccines induce low ...using cancer vaccines has not been reported in clinical trials conducted so ...with HER2-positive breast cancer is real but ...the HER2 ...
44
The human epidermal growth factor receptor 2 (HER2) in the breast cancer : from measurement to targeted treatment
... transactivate HER2 and represents therefore “escape” mechanism to circumvent the inhibitory effect of ...inhibit HER2 dimerization, it has been proposed that overexpression of other HER family members, in ...
334
How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer
... with HER2? tumours are now incor- porating the use of newer (neo)adjuvant treat- ments, such as pertuzumab and trastuzumab emtansine, which have shown to further improve the invasive DFS (iDFS) benefit gained with ...
14
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies
... computationally removed using a filter-based method 56 . In the analysis of primary tumors that are formalin-fixed, paraffin-embedded samples [FFPE] we further applied a filter to remove FFPE-related artifacts 57 ...
42
Overcoming therapeutic MAb resistance in agressive HER2 positive breast carcinomas by adoptive immunotherapy using optizimed effectors cells
... Sandrine Valsesia-Wittmann 1* , Beatrice Clemenceau 2 , Anne-Catherine Jallas 1 , Jean-Yves Blay 1 , Aurelien Marabelle 1 , Christophe Caux 1 , Henri Vie 2 From Society for Immunotherapy of Cancer 28th Annual ...
2
Progesterone receptor, obesity and prognosis in women diagnosed with estrogen receptor positive breast cancer
... the positive but not significative associations or half of the studies contradicting the other half ...poorer breast cancer-specific survival for women with HR+HER2−, but it was inconclusive ...
79
A mesofluidic multiplex immunosensor for detection of circulating cytokeratin-positive cells in the blood of breast cancer patients
... human breast cancer MCF7 cell line used herein underwent long-term passages (>70), thus gaining high expression of HER2 (Wang and Wang 2010 ...
10
Magi1, a new potential tumor suppressor gene in estrogen receptor positive breast cancer
... normal breast epithelial cells and ER + BC cells, however, loss of ER expression/function is associated with increased proliferation and aggressiveness [ 38 ...
23
Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?
... breast cancer-speci fic survival (BCSS) without systemic therapy of more than 88% among patients with ER+ tumors, and of more than 92% among patients with ER- ...age, HER2 status, axillary treatment, ...
22
Predictive and prognostic role of peripheral blood eosinophil count in triple negative and hormone receptor negative/HER2 positive breast cancers patients undergoing neoadjuvant treatment.
... Materials and methods We performed a retrospective analysis on 112 BC patients (79 triple negative, 33 HR-/HER2+), treated with standard NAC. The median follow-up was 37.5 months (range 9-156). Eosinophil and ...
1
Physical basis of the ‘magnification rule’ for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer
... of HER2-IHC is, however, more or less subjective which causes overall disagreement rates of around 10% [ 8 ...in breast cancer is false positive scoring while in gastric cancer false ...
7
Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study
... for HER2-positive tumors from since ...with positive hormonal receptors, and adjuvant 1-year trastuzumab for HER2-positive tumors, since ...
9
Reproductive factors and risk of hormone receptor positive and negative breast cancer: a cohort study.
... in breast tumors has become a standard part of breast cancer diagnosis and is used to predict endocrine therapy response ...PR positive expression, ER-PR- risk estimates remained ...on ...
13
The Huntington disease protein accelerates breast tumour development and metastasis through ErbB2/HER2 signalling
... to cancer cells while it renders them more sensitive to Trastuzu- mab ...a positive transcriptional regulator of genes involved in neuronal maintenance, a function that is lost when huntingtin is mutated ...
18